Expression of Glutathione-S-Transferase Isotypes in Relation to Doxorubicin Sensitivity and Prognosis in Patients With Renal-Carcinoma

Angus, Rachel; Lai, Tan-Chen; Collins, Cmp; Stonebridge, Br; Symes, M. O.

doi:10.3892/ijo.4.6.1383

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are in agreement with studies that showed an increased expression of GST-pi in RCC. In one study 76% of samples were positive for GST-pi (21), and in another study, 100% of samples (12/12) were positive (17). The five-year survival for patients with GST-pi positive tumors was 88% versus 50% for those with GST-pi negative tumors (21), a pattern reflected in our findings.…”

Section: Discussionmentioning

confidence: 96%

Glutathione-S-transferase-pi (GST-pi) expression in renal cell carcinoma

Kaprilian¹,

Horti²,

Kandilaris³

et al. 2015

jkcvhl

View full text Add to dashboard Cite

Multidrug resistance correlates with unfavourable treatment outcomes in numerous cancers including renal cell carcinoma. The expression and clinical relevance of Glutathione-S-transferase-pi (GST-pi), a multidrug resistance factor, in kidney tumors remain controversial. We analyzed the expression of GST-pi in 60 formalin-fixed, paraffin-embedded renal cell carcinoma samples by immunohistochemistry and compared them with matched normal regions of the kidney. A significantly higher expression of GST-pi was observed in 87% of clear cell carcinoma and 50% of papillary subtypes. GST-pi expression did not correlate with tumor grade or patient survival. GST-pi is unlikely to be a prognostic factor for renal cell carcinoma. However, further studies with large number of samples are warranted to establish the role of GST-pi, if any, in intrinsic or acquired resistance of renal cell carcinoma to conventional treatments.

show abstract

Section: Discussionmentioning

confidence: 96%